Evotec reports preliminary results: Berenberg target for Evotec stock is EUR 3.60

Published on 10/15/2026 at 09:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec expects EUR 465.00 million revenue for nine months. Evotec stock costs EUR 2.61 on October 15, 2026, 0.08 percent above Xetra close.

Preliminary results shape the outlook

Evotec expects EUR 465.00 million revenue for the first nine months of 2026 after its October 13, 2026 update.
Full-year 2026 revenue guidance remains EUR 570.00 million to EUR 610.00 million.
Evotec stock trades at EUR 2.61 at 9:35 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.08 percent above the Xetra close of October 14, 2026.
Complete third-quarter results are scheduled for November 5, 2026.

Extreme Makroaufnahme einer leuchtend blauen kristallinen Molekülstruktur — Makroaufnahme einer kristallinen Molekülstruktur verweist auf die Wirkstoffforschung von Evotec SE, ISIN DE0005664809, leuchtendes Blau, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) expects EUR 465.00 million in group revenue for the first nine months of 2026. EQS Group reported the preliminary figures on October 13, 2026, while Evotec also confirmed its full-year outlook. Berenberg's EUR 3.60 target adds a valuation reference, according to stock3 on October 14, 2026.

Three milestones shape the story

Evotec's recent chronology shows why the preliminary update matters. On July 14, 2026, the company cut its 2026 revenue outlook from EUR 700.00 million to EUR 780.00 million to EUR 570.00 million to EUR 610.00 million, as reported by stock3. On September 30, 2026, research chief Cord Dohrmann left after 16 years. On October 13, 2026, preliminary nine-month revenue reached EUR 465.00 million, with adjusted EBITDA at minus EUR 42.80 million.

What does the outlook mean for margins?

The revenue figure beat current market expectations, but the company attributed the variance mainly to the timing of consensus estimates. The confirmed full-year range of EUR 570.00 million to EUR 610.00 million therefore does not represent a new upgrade. Adjusted EBITDA is still expected between minus EUR 70.00 million and minus EUR 105.00 million for 2026, keeping profitability as the central test for the next report.

The comparison with the first nine months of 2025 remains demanding. Revenue was EUR 535.10 million in that period, versus EUR 465.00 million in the preliminary 2026 period, a calculated decline of 13.10 percent, according to stock3. The quarterly release will show whether the improved operating trend can continue beyond the timing effect.

Next reporting date is November 5

Evotec is scheduled to publish complete third-quarter and nine-month results on November 5, 2026, according to EQS Group. That release should provide the formal third-quarter numbers and a clearer view of the fourth-quarter revenue burden.

Evotec stock stays near EUR 2.61

Evotec stock was trading at EUR 2.61 at Lang & Schwarz on October 15, 2026 at 9:35 a.m. CEST, 0.08 percent above the Xetra close of October 14, 2026 at EUR 2.61. The small euro-area move leaves the preliminary results and the November reporting date as the main reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Evotec stock.